Cargando…

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

Mostrar otras versiones (1)

British Journal of Cancer (2002) 87, 1339–1339. doi:10.1038/sj.bjc.6600561 www.bjcancer.com © 2002 Cancer Research UK Correction to: British Journal of Cancer (2001) 84, 625–929. doi:10.1054/sj.bjc.2001.1975

Detalles Bibliográficos
Autores principales:	Gallagher, R, Hughes, C M, Murray, M M, Friery, O P, Patterson, L H, Hirst, D G, McKeown, S R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408906/ http://dx.doi.org/10.1038/sj.bjc.6600561

Ejemplares similares

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2001)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
por: Hejmadi, M. V., et al.
Publicado: (1996)

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
por: McKeown, S. R., et al.
Publicado: (1995)

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)

AQ4N: a new approach to hypoxia-activated cancer chemotherapy
por: Patterson, L H, et al.
Publicado: (2000)

Chemopotentiation of CCNU metabolites by misonidazole.
por: Mulcahy, R. T.
Publicado: (1985)

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
por: Bhattacharjee, Sayani, et al.
Publicado: (2022)

Chemopotentiation in vivo: no loss of sensitization with fractionation.
por: Hill, S. A., et al.
Publicado: (1984)

Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
por: Wheeler, K. T., et al.
Publicado: (1984)

Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes.
por: Teicher, B. A., et al.
Publicado: (1985)

Case of Poisoning by Aq. Ammonia
por: Patterson, A.
Publicado: (1857)

Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
por: Siemann, D. W.
Publicado: (1990)

Introduction to the AQ-WATCH Project and the AQ-WATCH Toolkit to fight air pollution
por: Li, C, et al.
Publicado: (2022)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

Assessment of NO(2) observations during DISCOVER-AQ and KORUS-AQ field campaigns
por: Choi, Sungyeon, et al.
Publicado: (2020)

Erratum: Measuring autistic traits in the general population: a systematic review of the Autism-Spectrum Quotient (AQ) in a nonclinical population sample of 6,900 typical adult males and females
por: Ruzich, Emily, et al.
Publicado: (2015)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
por: Workman, P., et al.
Publicado: (1989)

Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
por: Hodgkiss, R. J., et al.
Publicado: (1995)

Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
por: Adams, G. E., et al.
Publicado: (1984)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs.
por: Siim, B. G., et al.
Publicado: (1994)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Stereoselective Bioreduction of α-diazo-β-keto Esters
por: González-Granda, Sergio, et al.
Publicado: (2020)

Bioreduction: the biological activity, characterization, and synthesis of silver
por: KORKMAZ, Nesrin
Publicado: (2020)

Metagenomic ene-reductases for the bioreduction of sterically challenging enones
por: Dobrijevic, Dragana, et al.
Publicado: (2019)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

Reaction of Fe(aq)(II) with Peroxymonosulfate and Peroxydisulfate in the Presence of Bicarbonate: Formation of Fe(aq)(IV) and Carbonate Radical Anions
por: Kottapurath Vijay, Aswin, et al.
Publicado: (2023)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Rapid preparation process of antiparkinsonian drug Mucuna pruriens silver nanoparticle by bioreduction and their characterization
por: Arulkumar, Subramanian, et al.
Publicado: (2010)

Erratum to: Transportan 10 improves the anticancer activity of cisplatin
por: Rusiecka, Izabela, et al.
Publicado: (2016)

Erratum to: Synthetic and natural antioxidants attenuate cisplatin-induced vomiting
por: Alam, Javaid, et al.
Publicado: (2017)

Anthraquinone-2-sulfonic acid (AQ2S) is A Novel Neurotherapeutic Agent
por: Jackson, T C, et al.
Publicado: (2013)

Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35 (2018) 204–221]
por: Guo, Jiwei, et al.
Publicado: (2021)

Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
por: Janssens, M Y, et al.
Publicado: (1999)

Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro
por: Tomita, Yoko, et al.
Publicado: (2019)

Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871
por: Rodriguez, Emma, et al.
Publicado: (2021)

Erratum to: TOPK Activation Exerts Protective Effects on Cisplatin-induced Acute Kidney Injury
por: Zhang, Hui, et al.
Publicado: (2022)

Erratum to: Study protocol: evaluation of a parenting and stress management programme: a randomised controlled trial of Triple P Discussion Groups and Stress Control
por: Palmer, Melanie L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cbdun4gg33iicavbd2vualju3j